Tazarotene/Betamethasone Dipropionate

他扎罗汀/倍他米松二丙酸酯

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTazarotene/Betamethasone Dipropionate
Drug Alias Name他扎罗汀倍他米松
ClassificationSmall molecules > Steroids
Mechanisms of ActionRetinoic acid receptor gamma agonistsRetinoic acid receptor alpha agonistsGlucocorticoid receptor agonists +[4] 
TargetsGlucocorticoid receptorRetinoic acid receptor betaRetinoic acid receptor gamma +[4] 
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsPsoriasis
Approved Indications in ChinaPsoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2015/03/27
Country/TerritoryMainland China
CombinationsYes TazaroteneBetamethasone Dipropionate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChongqing Huapont Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Huapont Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeD05
Related LinksN/A